Technology empowers the dual brand matrix, Guangdong Marubi Biotechnology accelerates the construction of competitive barriers for the cosmetics industry.

"In the past, people used to buy skincare products based on advertisements, but now they buy skincare products by checking the ingredient list. With the Z generation embracing the concept of pure beauty products, a rational consumer group focusing on product ingredients and efficacy has become the mainstream in the market. The '2025 Double 11 Apparel and Beauty Consumption Trend Research Report' shows that over 90% of respondents believe that researching fabric when buying clothes and researching ingredients when buying skincare products are wiser consumer choices. Nearly half of the consumers emphasize that consumption should focus on 'the most essential elements of a product.' This shift in market trends is also affecting the strategic layout of businesses. Recently, Guangdong Marubi Biotechnology, with "biotechnology beauty" at its core, has officially submitted an IPO application to the Hong Kong Stock Exchange. The company had already entered the A-share market in 2019 as the first eye cream stock. If successful in listing in Hong Kong, Guangdong Marubi Biotechnology will become a dual-platform listed company on the "A+H" markets. This move not only expands international financing channels but also helps enhance the brand's influence in the global market, pushing the company into a new stage of development. Focusing on restructuring collagen to create a new paradigm in beauty technology In an increasingly competitive beauty industry, brand core barriers are shifting from marketing and distribution to deeper levels of technological research and ingredient innovation. In recent years, Guangdong Marubi Biotechnology has focused on empowering the beauty industry with biotechnology, targeting anti-wrinkle, firming, and repair skincare products. The company has built an integrated research and development platform covering basic research, pilot production, experimentation, and production preparation. It is worth noting that from 2022 to the present, the company has invested over 250 million yuan in research and development. It has established cooperation networks with approximately 30 top universities and research institutions worldwide, acquiring a total of 375 authorized patents, including 265 invention patents, making it the leading beauty company in China in terms of patented inventions. Leveraging solid research and development investment and deep accumulation in synthetic biology, the company has made breakthrough progress in restructuring collagen, a key anti-aging ingredient. By successfully developing recombinant dual collagen, the company has merged type I collagen, which determines skin contours, with type III collagen, responsible for skin filling elasticity, into a single molecule using the "translation pause" and "C-PRO loop" technologies. This has substantially improved the similarity, bioactivity, stability, and scalability of recombinant dual collagen to human collagen. As of September 30, 2025, the company has developed over 80 proprietary ingredients, including recombinant dual collagen, with over 30 already in large-scale production, and its research achievements are rapidly entering the market. Supported by robust research and development capabilities, Guangdong Marubi Biotechnology has established a clear and synergistic dual-brand matrix. The main brand, "Marubi," focuses on anti-wrinkle and firming eye and facial care solutions, leading in the segmented market track and ranking as the top eye care brand in China in terms of retail sales from 2021 to 2024. The second brand, "Lianhuo," focuses on high-quality and cost-effective base makeup and color cosmetics. Its retail sales compound annual growth rate reached 77.5% from 2022 to 2024, leading in growth among the top five base makeup brands in China. By 2024 retail sales, "Lianhuo" had entered the top five base makeup brands in China and had exceeded 500 million yuan in revenue in the first half of 2025, a year-on-year growth of 23.87%, expecting to surpass 1 billion yuan for the full year, becoming another star brand under the company. The company's solid product strength is also reflected in its excellent financial performance. From 2022 to 2024, the company's revenue increased from 1.732 billion yuan to 2.97 billion yuan, with a compound annual growth rate of 31%. Net profit increased from 167 million yuan to 342 million yuan, with a compound annual growth rate of 43%, showing significant high-speed growth momentum. Meanwhile, the company has made significant progress in channel transformation, with a notable improvement in channel revenue structure. The proportion of online direct sales revenue increased from 46.4% in 2022 to 74.8% in the first three quarters of 2025, continuously strengthening its direct connection with consumers through mainstream e-commerce platforms such as Douyin, Tmall, and Kuaishou. Currently, the company's research and innovation strength has received dual official and market certifications: In 2023, Guangdong Marubi Biotechnology was approved by the Ministry of Industry and Information Technology as the main drafting unit for the industry standard "Recombinant Soluble Collagen" and is currently the first and only approved "National Recombinant Functional Protein Technology Research Center" in China. By 2024 retail sales, the company is the third largest beauty company in the field of recombinant collagen skincare products, establishing a solid competitive moat. Overall, as consumers pay more attention to product ingredients and technological content, Guangdong Marubi Biotechnology, with its continuous investment in biotechnology, clear brand layout, and healthy profit performance, has taken an important position in the technological transformation of domestic beauty products. As the "A+H" listing process advances, the company's future development space is worthy of more market investors' expectations."